A5006534529- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Vibrio bacteria research studies
- Bacterial Identification and Susceptibility Testing
- Antibiotic Use and Resistance
- Urinary Tract Infections Management
- Pharmaceutical and Antibiotic Environmental Impacts
- Enterobacteriaceae and Cronobacter Research
- Mycobacterium research and diagnosis
- Bacterial biofilms and quorum sensing
- COVID-19 Clinical Research Studies
- Escherichia coli research studies
- Pneumonia and Respiratory Infections
- Infections and bacterial resistance
- SARS-CoV-2 and COVID-19 Research
- Antimicrobial Resistance in Staphylococcus
- Genomics and Phylogenetic Studies
- Salmonella and Campylobacter epidemiology
- Pneumocystis jirovecii pneumonia detection and treatment
- SARS-CoV-2 detection and testing
- Infective Endocarditis Diagnosis and Management
- Long-Term Effects of COVID-19
- Antimicrobial Peptides and Activities
- Tuberculosis Research and Epidemiology
- Bacterial Genetics and Biotechnology
University of Pittsburgh
2016-2025
Fujita Health University
2017-2025
Fujita Health University Hospital
2019-2025
Office of Infectious Diseases
2008-2024
University of Pittsburgh Medical Center
2012-2023
Duke University Hospital
2023
Duke Medical Center
2023
Osaka University
2022-2023
CNR de la Résistance aux Antibiotiques
2022
National Institute of Infectious Diseases
2000-2021
The efficacy of ceftazidime-avibactam—a cephalosporin–β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase–producing carbapenem-resistant Enterobacteriaceae (CRE)—compared colistin remains unknown. Patients initially treated either ceftazidime-avibactam or for CRE infections were selected from the Consortium on Resistance Against Carbapenems and other (CRACKLE), a prospective, multicenter, observational study. Efficacy, safety, benefit-risk...
Methylation of 16S ribosomal RNA (rRNA) has recently emerged as a new mechanism resistance against aminoglycosides among gram-negative pathogens belonging to the family Enterobacteriaceae and glucose-nonfermentative microbes, including Pseudomonas aeruginosa Acinetobacter species. This event is mediated by newly recognized group rRNA methylases, which share modest similarity those produced aminoglycoside-producing actinomycetes. Their presence confers high level all parenterally administered...
Klebsiella pneumoniae producing carbapenemase (KPC) has been associated with serious infections and high mortality. The optimal antimicrobial therapy for infection due to KPC-producing K. is not well established. We conducted a retrospective cohort study evaluate the clinical outcome of patients bacteremia caused by pneumoniae. A total 41 unique blood cultures growing were identified at two medical centers in United States. Most hospital acquired (32; 78%), while rest cases health care (9;...
ABSTRACT There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, treatment Klebsiella pneumoniae bacteremia was associated higher rates clinical success ( P = 0.006) and survival 0.01) than other regimens. Across groups, there were differences in underlying diseases, severity illness, source bacteremia, or strain characteristics (97% produced K. carbapenemase)....
ABSTRACT Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment CRE infections and identify mechanisms. Ceftazidime-avibactam-resistant K. emerged in three patients after for 10 19 days. Whole-genome sequencing (WGS) longitudinal ceftazidime-avibactam-susceptible...
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days 59% (22/37) 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance detected in 30% (3/10) microbiologic failures.
Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, resistance is emerging. Methods. Patients with infection or colonization due colistin-resistant A. were identified at a hospital system Pennsylvania. Clinical data collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) performed. To investigate mechanism...
The effect of procalcitonin-guided use antibiotics on treatment for suspected lower respiratory tract infection is unclear.In 14 U.S. hospitals with high adherence to quality measures the pneumonia, we provided guidance clinicians about national clinical practice recommendations infections and interpretation procalcitonin assays. We then randomly assigned patients who presented emergency department a whom treating physician was uncertain whether antibiotic therapy indicated one two groups:...
Natural History of Asymptomatic SARS-CoV-2 Infection The outbreak on the cruise ship Diamond Princess led to identification 96 persons who were infected with but asymptomatic...
Background. The occurrence of community-associated infections due to extended-spectrum β-lactamase (ESBL)–producing Escherichia coli has been recognized as a major clinical problem in Europe and other regions.
Data on the use of ceftolozane-tazobactam and emergence resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infections are limited.We performed a retrospective study 21 patients treated with for MDR-P. infections. Whole genome sequencing quantitative real-time polymerase chain reaction were longitudinal isolates.Median age was 58 years; 9 (43%) transplant recipients. Median simplified acute physiology score-II (SAPS-II) 26. Eighteen (86%) respiratory tract infections; others...